SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Overview of the Hatch-Waxman Act and its impact on the drug development process.
0 references·7 citing·33 second hop
Overview of the Hatch-Waxman Act and its impact on the drug development process. (1999)Overview of the Hatch-Waxman Act and its …US Pharma's Financialized Business Model (2017)US Pharma's Financialized Bus…Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry (2016)Regulation and welfare: evide…Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom (2016)Quantifying the economic impa…Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry (2011)Regulation and Welfare: Evide…Intellectual Property, Information Technology, Biomedical Research, and Marketing of Patented Products (2011)Intellectual Property, Inform…Follow-on biologics: data exclusivity and the balance between innovation and competition (2008)Follow-on biologics: data exc…The Market For Follow-On Biologics: How Will It Evolve? (2006)The Market For Follow-On Biol…A New Approach to Consumer Theory (1966)Conditional logit analysis of qualitative choice behavior (1972)Discrete Choice Methods with Simulation (2001)The impact of advance purchase deadlines on airline consumers’ search and purchase behaviors (2015)The price of innovation: new estimates of drug development costs (2003)Generic Competition in the US Pharmaceutical Industry (2006)The cost of biopharmaceutical R&D: is biotech different? (2007)IP Issues of Therapeutic Antibodies (2012)The biotechnology sector and US gene patents: Legal challenges to intellectual property rights and the impact on basic research and development (2012)Determinants of Market Exclusivity for Prescription Drugs in the United States (2017)Industrial Market Structure and Economic Performance. (1971)Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not) (2000)Extending the Limits of Protection of Pharmaceutical Patents and Data Outside the EU – Is There a Need to Rebalance? (2014)Distribution of the Estimators for Autoregressive Time Series with a Unit Root (1979)Co-Integration and Error Correction: Representation, Estimation, and Testing (1987)Generalized impulse response analysis in linear multivariate models (1998)The Human Right to Health (2011)Public sector financial support for late stage discovery of new drugs in the United States: cohort study (2019)Toward a New Common Sense (2021)An evolutionary theory of economic change (1982)Capital-Market Imperfections and Investment (1997)Performance Pay and Top-Management Incentives (1990)Agency costs of free cash flow, corporate finance, and takeovers (1996)Diagnosing the decline in pharmaceutical R&D efficiency (2012)The Shareholder Value Mess (And How to Clean it Up) (2019)The United States as Radical Innovation Driver: The Politics of Declining Dominance? (2021)Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019 (2023)Automobile Prices in Market Equilibrium (1995)The Regulation of Entry (2000)Discrete Choice Methods with Simulation (2003)THE WELFARE IMPACT OF PARALLEL IMPORTS: A STRUCTURAL APPROACH APPLIED TO THE GERMAN MARKET FOR ORAL ANTI‐DIABETICS (2014)Dynamic impact of uncertainty on R&D cooperation formation and research performance: Evidence from the bio-pharmaceutical industry (2017)What is the impact of intellectual property rules on access to medicines? A systematic review (2022)
this work references cited by second hop

References

No references inside the corpus for this window.

Cited by

  • 2016Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry124 cited
  • 2016Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom121 cited
  • 2011Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry96 cited
  • 2008Follow-on biologics: data exclusivity and the balance between innovation and competition89 cited
  • 2017US Pharma's Financialized Business Model80 cited
  • 2006The Market For Follow-On Biologics: How Will It Evolve?79 cited
  • 2011Intellectual Property, Information Technology, Biomedical Research, and Marketing of Patented Products6 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work